Image source: Shutterstock

Highlights:

  • NAV Growth: Net Asset Value per share rose 2.4% to 178.08p over six months.
  • Market-Leading Returns: Ranked first among 20 peer group funds, with 5.4%, 43.8%, and 241.0% returns over six months, one year, and five years, respectively.
  • Strategic Investments: 194.4 million MMI shares issued to the Fund, and De La Rue Plc received a £300 million offer for its Authentication Division.

Crystal Amber Fund Limited (LSE:CRS) has reported a 2.4% increase in Net Asset Value (NAV) per share for the six-month period ending 31 December 2024, reaching 178.08p. The Fund outperformed its peer group, ranking first out of 20 similar funds in terms of returns over six months, one year, and five years.

Market-Leading Performance and Key Investments

According to Trustnet, Crystal Amber Fund generated returns of 5.4% over six months, 43.8% over one year, and an impressive 241.0% over five years. These figures significantly outpaced the average peer group returns of -6.7%, 7.2%, and 95.5%, respectively. The Fund also conducted a £1.4 million share buyback during the period at an average 43.3% discount to NAV, further enhancing asset value.

The Fund’s investment in Morphic Medical Inc. (MMI) has shown promising developments. With regulatory approval expected soon, the company has made substantial operational progress. Following a previous announcement on 13 January 2025, Crystal Amber Fund has received 194.4 million common shares in MMI, resulting from the conversion of $25.4 million in loan notes and $3 million in accrued interest.

Another key investment, De La Rue Plc, received a binding offer to sell its Authentication Division for £300 million. Additionally, the company has been subject to takeover approaches following the reporting period, signaling strong market interest in its assets.